Page last updated: 2024-08-24

oseltamivir and ER-Negative PR-Negative HER2-Negative Breast Cancer

oseltamivir has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR1

Other Studies

1 other study(ies) available for oseltamivir and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; CD24 Antigen; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Hyaluronan Receptors; Metformin; Oseltamivir; Retinal Dehydrogenase; Spheroids, Cellular; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Cells, Cultured

2020